Skip to content

Treatment of High-Risk Moderate Acute Malnutrition Using Expanded Admission Criteria

Treatment of High-Risk Moderate Acute Malnutrition Using Expanded Admission Criteria (Hi-MAM Study): A Cluster-randomized Controlled Trial Protocol

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03647150
Acronym
Hi-MAM
Enrollment
1322
Registered
2018-08-27
Start date
2018-11-13
Completion date
2020-06-05
Last updated
2020-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition

Brief summary

This project explores whether children have better growth and cognitive development when the clinic identifies higher risk MAM children and support them either with the same treatment as SAM children or with the recommended practice: nutrition counseling.

Detailed description

This is a cluster-randomized controlled trial taking place in 20 community clinics providing malnutrition care in Sierra Leone. All participants will be children aged 6-59 months. Control participants will have moderate acute malnutrition (MAM), defined as mid-upper arm circumference (MUAC) 11.5-\<12.5. High Risk MAM will be defined with a MUAC 11.5 to \<11.9 or WAZ\<-3.5 or Mother not the caretaker or not breastfeeding at \<2 years old. Low risk MAM defined with a MUAC 11.9 to \<12.5 with no risk factors. Control group and low risk group caregiver's will received nutrition education via mother care groups every two weeks for 6 weeks and will be followed up 12 and 24 weeks post-enrollment. High risk group will receive 1 week supply of amoxicillin at enrollment and 1 sachet of RUTF per day till MUAC is equal to or greater than 12.5 or up to 12 weeks of treatment. Their caregiver will also receive nutrition education via the mother care groups. The investigators will also follow up with the participant at 12 and 24 weeks post-enrollment. A subset of the participants in each group will also be enrolled in a cognitive development substudy were the investigators will be using a eye tracking performance assessment. Investigators will also enroll health adult participants for eye tracking assessment. Adult data will be used as a reference when interpreting results.

Interventions

DRUGamoxicillin

At enrollment the child will receive a 1 week course of amoxicillin

1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed

BEHAVIORALMother Care group

Nutrition education via mother care groups lead by a respected elder in the local community

Sponsors

Centre for Global Child Health, Hospital for Sick Kids, Toronto, Canada
CollaboratorUNKNOWN
Department of Psychology, University of Tampere, Finland
CollaboratorUNKNOWN
Project Peanut Butter, Sierra Leone
CollaboratorUNKNOWN
Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Months to 59 Months
Healthy volunteers
No

Inclusion criteria

* uncomplicated MAM (based on MUAC equal to or greater than 11.5 cm and \<12.5)

Exclusion criteria

* currently involved in another research trial or feeding program * medical complication such as oedema, severe nausea/vomiting, severe dehydration, or severe pneumonia * have a diagnosed or visible sign of developmental delay * have a history of peanut or milk allergy

Design outcomes

Primary

MeasureTime frameDescription
Recovery from moderate acute malnutrition (MAM)up to 12 weeks of treatmentproportion of participants recovered based on mid-upper arm circumference(MUAC) Recovery is defined as MUAC greater than or equal to 12.5cm before or at 12 weeks after enrollment.

Secondary

MeasureTime frameDescription
Participants deterioration to severe acute malnutrition(SAM)Duration of the study 24 weeks post-enrollmentProportion of participants that deteriorate from moderate acute malnutrition(MAM) to severe acute malnutrition(SAM). SAM is defined at mid-upper arm circumference(MUAC)\<11.5 or presence of oedema.
Participants that remain or become underweight using weight for age z-score24 weeks post-enrollmentthe difference between the weight for age z-score(WAZ) from enrollment to 24 weeks post-enrollment
Participant survival ratesDuration of the study 24 weeks post-enrollmentProportion of participants survival rates during the study
Participants that remain or become Wasted24 weeks post-enrollmentthe difference between weight for length z-score(WHL) from enrollment to 24 weeks post enrollment
Eye tracking performance for cognitive development24 weeks post enrollmentthe difference between the eye tracking performance from enrollment to 24 weeks post enrollment
Participants that remain or become Stunted24 weeks post-enrollmentthe difference between length for age z-score(LAZ) from enrollment to 24 weeks post enrollment

Countries

Sierra Leone

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026